The Association of G9a Protein and the Outcome of Patients With Cervical Cancer
September 4, 2016 updated by: Sheng-Mou Hsiao, Far Eastern Memorial Hospital
G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer.
Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
69
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Taipei
-
Banqiao, New Taipei, Taiwan, 22050
- Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Patients with cervical cancer, and underwent primary treatment (surgery, radiotherapy or chemotherapy) in Far Eastern Memorial Hospital
Description
Inclusion Criteria:
- cases with cervical cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
cervical cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer
Time Frame: From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months
|
From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer
Time Frame: From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months
|
From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
February 1, 2015
Study Completion (Actual)
February 1, 2015
Study Registration Dates
First Submitted
December 27, 2011
First Submitted That Met QC Criteria
January 6, 2012
First Posted (Estimate)
January 9, 2012
Study Record Updates
Last Update Posted (Estimate)
September 7, 2016
Last Update Submitted That Met QC Criteria
September 4, 2016
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 100078-E
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.